Booster dose after 10 years is recommended following 17DD-YF primary vaccination

Autor: Jordana Grazziela Coelho-dos-Reis, Luiza Pacheco-Porto, Marisol Simões, Carla Magda Allan Santos Domingues, Iramaya Rodrigues Caldas, Pedro Luiz Tauil, Marcos Dornelas-Ribeiro, Gabriela Villela-Rezende, Cristina Toscano Fonseca, Aline de A Vinhas, Lis Ribeiro do Valle Antonelli, Ana Carolina Campi-Azevedo, Alessandro Pecego Martins Romano, Akira Homma, J. F. M. Pereira, Olindo Assis Martins-Filho, Raiany Araujo Santos, Maurício Azevedo Batista, Maria Rios, Fernanda Magalhães Freire Campos, Reinaldo de Menezes Martins, Tatiane Rocha Alves, Jandira Aparecida Campos Lemos, Andréa Teixeira-Carvalho, Harold Richard Persi, Maria de Lourdes de Sousa Maia, José Ailton de Souza Martins, Otoni A Melo Júnior, Pedro Fernando da Costa Vasconcelos, Roberto Henrique Guedes Farias, Matheus Fernandes Costa-Silva, Mirian Mariano de Souza, Christiane Costa-Pereira, Tatiana Guimarães de Noronha, Vanessa dos Reis von Doellinger, Luiz Antonio Bastos Camacho, Luiz Cosme Cotta Malaquias, Jaquelline Germano de Oliveira, Débora M S H Hossell, Marcos da Silva Freire, Vanessa Peruhype-Magalhães
Jazyk: angličtina
Rok vydání: 2016
Předmět:
CD4-Positive T-Lymphocytes
0301 basic medicine
medicine.medical_treatment
Primary vaccination
Citometria de Fluxo / m?todos
Booster dose
CD8-Positive T-Lymphocytes
Antibodies
Viral
memory cells and vaccination
vaccine
cytokine
Immunology and Allergy
B-Lymphocytes
education.field_of_study
biology
Vaccination
Yellow Fever Vaccine
Yellow fever
Research Papers
Febre Amarela / imunologia
Cytokine
Fatores de Tempo
Yellow fever virus
Antibody
Brazil
Immunology
Population
Imuniza??o Secund?ria
yellow fever
Interferon-gamma
03 medical and health sciences
medicine
Humans
Vacina contra Febre Amarela / administra??o & dosagem
education
Pharmacology
Tumor Necrosis Factor-alpha
business.industry
flow cytometry
medicine.disease
Antibodies
Neutralizing
Vacina contra Febre Amarela / imunologia
030104 developmental biology
Imunidade / imunologia
biology.protein
duration of immunity
business
Immunologic Memory
CD8
Febre Amarela / preven??o & controle
Zdroj: Repositório Digital do Instituto Evandro Chagas (Patuá)
Instituto Evandro Chagas (IEC)
instacron:IEC
Human Vaccines & Immunotherapeutics
Popis: Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Governo do Estado de Minas Gerais. Secretaria de Estado de Sa?de. Belo Horizonte, MG, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Universidade Federal de Alfenas. Alfenas, MG, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Instituto de Biologia do Exercito. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Assessoria Cl?nica de Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Funda??o Oswaldo Cruz. Assessoria Cl?nica de Bio-Manguinhos. Rio de Janeiro, RJ, Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Brasil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Brasil. Universidade de Bras?lia. Brasilia, DF, Brasil. Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil. US Food and Drug Administration. Center for Biologics Evaluation and Research. Silver Spring, MD USA Funda??o Oswaldo Cruz. Diretoria Regional de Bras?lia. Bras?lia, DF, Brasil. Funda??o Oswaldo Cruz. Escola Nacional de Sa?de Publica. Rio de Janeiro, DF, Brasil. Funda??o Oswaldo Cruz. Centro de Pesquisas Ren? Rachou. Belo Horizonte, MG, Brasil. A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT?2.9Log10mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to na've baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-?(+) and IFN-?(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the na've baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination.
Databáze: OpenAIRE
Externí odkaz: